A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

Launched by AHS CANCER CONTROL ALBERTA · Mar 12, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help patients with advanced papillary thyroid cancer, especially those whose cancer has stopped responding to standard treatments using radioactive iodine. The study is testing a drug called imatinib, which has been used to treat other cancers. Researchers believe that imatinib can help restore the cancer cells' ability to absorb radioactive iodine, allowing the treatment to work again and potentially shrink tumors. This could help patients live longer and improve their quality of life.

To participate in this trial, patients need to be at least 18 years old and have a confirmed diagnosis of papillary thyroid cancer that is advanced or has spread and is not treatable with surgery or radiation. They must also have cancer that does not respond to radioactive iodine. Participants will receive imatinib along with regular follow-up visits to monitor their health and the progress of the treatment. It's important for patients to discuss this opportunity with their healthcare team to see if they meet the criteria and if this trial is right for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Cytologically or histologically confirmed papillary thyroid cancer consisting of papillary or follicular variants.
• 2. Radioiodine-refractory disease (iodine-refractory thyroid cancer) by at least one of the following criteria:
• • 1. an index metastatic lesion that was not radioiodine-avid on diagnostic radioiodine scanning performed within 28 days of enrolment;
• • 2. a radioiodine-avid metastatic lesion that remained stable in size or progressed despite radioiodine treatment 3 months or more before entry into the study; or
• • 3. 18F-fluorodeoxyglucose (FDG)-avid lesions on PET scan (if available). 3. Recurrent, advanced, or metastatic (Stage IV) disease that is not amenable to surgical resection or radiation with curative intent.
• • 4. Minimal or no radioactive iodine uptake demonstrated by whole body iodine scans.
• • 5. Age ≥ 18. 6. Eastern Cooperative Oncology (ECOG) performance status of ≤ 1. 7. Presence of measurable disease, defined as at least 1 unidimensional measurable lesion on a computed tomography (CT) scan as defined by RECIST 1.1.
• • 8. Hematology: WBC ≥ 3.0 x 109/L or granulocytes (polymorphs + bands) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L within 4 weeks prior to enrolment.
• • 9. AST (SGOT) and/or ALT (SGPT) and alkaline phosphatase ≤ 5 x the upper limit of normal (ULN). Creatinine ≤ 1.5 x ULN.
• • 10. Serum amylase and lipase ≤ 1.5 x ULN 11. Serum potassium, phosphorus, magnesium and calcium ≥ lower limit of normal or correctable with supplements prior to first dose of study drug.
• • 12. Be able to comply with study procedures and follow-up examinations. 13. Not pregnant or lactating. Male and female patients who are fertile must agree to use an effective means of birth control (i.e., latex condom, diaphragm, cervical cap, etc.) to avoid pregnancy.
• • 14. Sign a written informed consent.
• Exclusion Criteria:
• • 1. Has received radiation therapy within 21 days of Study Day 1. 2. Has had major surgery within 21 days of Study Day 1. 3. Has untreated brain or meningeal metastases. Patients who have treated brain metastasis (via local radiation standards or surgical resection or local ablative techniques) and who are either off steroids or on a stable dose of steroids for at least one month (30 days), AND who are off anticonvulsants, AND have radiological documented stability of lesions for at least 3 months may be eligible. Each case should be discussed with the Principal Investigator.
• • 4. Has a central thoracic tumor lesion as defined by location within the hilar structures.
• • 5. Has proteinuria CTCAE v.4.0 Grade \> 1 at baseline. 6. Has a history of, or currently exhibits clinically significant cancer related events of bleeding.
• • 7. Currently exhibits untreated, symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) \> 90 mm Hg or systolic BP \> 140 mm Hg.
• • 8. Has a history of myocardial infarction, stroke or Transient Ischemic Attack (TIA) within 6 months of Study Day 1.
• 9. Impaired cardiac function including any of the following:
• • 1. Has a documented left ventricular (LV) ejection fraction \< 50%;
• • 2. Long QT syndrome or family history of long QT syndrome;
• • 3. Clinically significant resting bradycardia (\<50 bpm);
• • 4. Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina, significant ventricular or atrial tachyarrhythmia).
• • 10. Treatment with strong CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
• • 11. Treatment with strong CYP3A4 inducers (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
• • 12. Patients using medication that have been documented to prolong QT interval should be avoided. In the case it is not possible to avoid or switch to other medication, patients should be followed with caution and ECG testing should be requested at least every 3 months after starting study or if any dose change occurs or if clinical symptoms appear.
• • 13. Has known autoimmune disease with renal involvement (e.g. lupus). 14. Receiving combination anti-retroviral therapy for HIV. 15. Has clinically significant uncontrolled condition(s). 16. Previous or concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or uterus or non-melanoma skin cancer or in-situ carcinoma of the prostate (Gleason score ≤ 7, with all treatment being completed 6 months prior to enrollment, unless at least 5 years have elapsed since last treatment and the patient is considered cured).
• • 17. Has active ulcerative colitis, Crohn's disease, celiac disease, short gut syndrome from any cause, or any other conditions that interfere with absorption.
• • 18. History of acute pancreatitis within one year of study entry or medical history of chronic pancreatitis.
• • 19. Has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
• • 20. Pregnant or breast feeding. 21. History of non-compliance to medical regimens or inability to grant consent.
• • 22. Use of an investigational agent within 28 days prior to enrollment in the study or foreseen use of an investigational agent during the study.